A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma
Status:
Terminated
Trial end date:
2007-06-01
Target enrollment:
Participant gender:
Summary
In Phase I, patients will receive a combination of PS-341 (Velcade) and R115777 (Zarnestra)
to determine the dose limiting toxicity (DLT). Once DLT is determined, patients in Phase II
will be receive the maximum tolerated dose (MTD) to complete 8 cycles of therapy. Treatment
will continue if there is evidence of continued response for 8 cycles. Patients will receive
follow up to include normal laboratory evaluations at least every 3 months and a skeletal
survey will be performed at least every 6 months.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
H. Lee Moffitt Cancer Center and Research Institute
Collaborators:
Millennium Pharmaceuticals, Inc. National Cancer Institute (NCI)